Replies to post #237243 on Biotech Values

[DewDiligence]

ASMB 1Q21 results:

https://finance.yahoo.com/news/assembly-biosciences-reports-first-quarter-200500927.html

Cash, cash equivalents and marketable securities were $214.9 million as of March 31, 2021, compared to $216.4 million as of December 31, 2020. This result includes $34.1 million of net proceeds from the issuance of common shares under Assembly Bio’s at-the-market (ATM) program.

No CC.